• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact

    8/13/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce.

    FAIRFIELD, N.J., Aug. 13, 2025 /PRNewswire/ -- The Healthcare Businesswomen's Association (HBA) today announced the recipients of its 2025 Advancement, Commitment, and Engagement (ACE) Awards, honoring high-impact programs that are redefining workforce development across the healthcare industry. The ACE Awards recognize standout programs with bold strategies that prioritize people, scale globally, deliver measurable business and social outcomes, and honor the future of leadership and innovation in healthcare. This year's honorees include:

    Healthcare Businesswomen's Association (PRNewsfoto/Healthcare Businesswomen's Association)

    • AstraZeneca, Young Health Programme (YHP), 2025 ACE Award
    • Viseven, Expert Communities and Unicorns Recognition Program, 2025 ACE Aspire Award

    "The ACE Awards highlight leadership that redefines workforce development in healthcare," said Mary Stutts, CEO of the Healthcare Businesswomen's Association. "AstraZeneca and Viseven have both demonstrated how strategic, purpose-driven programs can empower talent, foster innovation, and generate meaningful business outcomes. This level of commitment to people-centered growth is essential for advancing the entire healthcare ecosystem."

    About AstraZeneca's Young Health Programme (YHP)

    The HBA ACE Award honors established programs that have demonstrated measurable success in engagement, innovation, and workforce development. AstraZeneca was recognized with the 2025 ACE Award for its long-standing Young Health Programme (YHP), a global health equity initiative focused on the prevention of non-communicable diseases (NCDs) – including cancer, diabetes, heart disease and respiratory disease – while also cultivating purpose-driven leadership among employees.

    Celebrating its 15th year, the YHP is a community-driven program that seeks to advance health equity by activating underserved youth to reduce their risk of NCDs through peer education, local partnerships, and youth advocacy. To date, the initiative has directly reached more than 20 million young people across more than 40 countries in partnership with more than 60 not-for-profit organizations, including UNICEF and Plan International, while also mobilizing 20,000 AstraZeneca employees who have contributed nearly 100,000 hours of volunteer service.

    YHP not only tackles critical global health challenges, but it strengthens AstraZeneca's internal culture by connecting employees to meaningful work and volunteering opportunities that extend beyond their day-to-day roles. The program, through its youth leaders, has positively influenced 18 NCD prevention-related policies worldwide and continues to create leadership pathways for both youth and employees, driving sustainable impact across communities and within the company itself.

    "We are honored to receive the HBA ACE Award for the Young Health Programme," said Marc Dunoyer, Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca and Young Health Programme Senior Executive Team Sponsor. "The Young Health Programme demonstrates our commitment to communities and truly reflects our corporate values. By focusing on prevention and supporting young people to make informed health choices, YHP is helping to shape healthier futures – a transformative approach that will have a lasting impact for generations to come."

    About Viseven's Expert Communities and Unicorns Recognition Program

    The HBA ACE Aspire Award honors emerging programs that demonstrate strong early outcomes and the potential for lasting impact. Viseven was selected as the 2025 Aspire Award recipient for its Expert Communities and Unicorns Recognition Program – a newly launched initiative transforming how the company fosters internal engagement, collaboration, and culture.

    Introduced in 2024, the program consists of two core components: Expert Communities, which promote cross-functional learning and professional development in key areas like project management, finance, and client engagement; and the Unicorns Recognition Program, a gamified platform where employees award "UniCoins" to peers who exemplify Viseven's core values: passion, agility, curiosity, and empathy.

    With more than 700 employees engaged to date, these initiatives are surfacing internal talent, enhancing peer connection, and building a scalable culture of innovation, appreciation, and shared growth – setting a powerful foundation for long-term organizational success.

    "We are incredibly honored to receive the 2025 ACE Aspire Award from the HBA," said Nataliya Andreychuck, CEO and Co-founder, Viseven. "At Viseven, we believe that sustainable growth begins with a strong internal culture. The Expert Communities and Unicorns Recognition Program is our way of investing in people – empowering them to lead, grow, and innovate together. This recognition affirms that putting people at the center of transformation isn't just the right thing to do – it's also how we build the future of healthcare."

    Event Details and Contact

    The HBA will honor both AstraZeneca and Viseven during the 2025 HBA Annual Conference, hosted in Las Vegas, Nevada, from 29 September through 1 October. For inquiries about media passes to the HBA's 2025 Annual Conference, interview opportunities, or information about the HBA's signature award programs, please contact Hannah McKee, Senior Manager of Communications & Media Relations, at [email protected].

    About the Healthcare Businesswomen's Association (HBA)

    The Healthcare Businesswomen's Association (HBA) is a global leadership accelerator, talent pipeline, and business growth partner for the healthcare industry. With a presence spanning 80 locations, the HBA supports more than 150 Corporate Partners and impacts a workforce of nearly six million employees. The HBA empowers healthcare leaders at every stage of their careers through global forums, programs that prepare the future healthcare workforce, and recognition initiatives celebrating outstanding individuals and organizations.

    About AstraZeneca

    AstraZeneca (NASDAQ:AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. For details on how to contact the Investor Relations Team, please click here. For Media contacts, please here.

    About Viseven

    Viseven enables global life sciences organizations to deliver compliant and impactful experiences to HCPs & Patients through a scalable end-to end solution that covers strategy, operational excellence, and technology enablement.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-healthcare-businesswomens-association-hba-honors-astrazeneca-and-viseven-with-2025-ace-awards-for-workforce-innovation-and-global-impact-302528387.html

    SOURCE Healthcare Businesswomen's Association

    Get the next $AZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN

    DatePrice TargetRatingAnalyst
    1/27/2026Buy
    Citigroup
    10/27/2025Buy
    Jefferies
    10/16/2025Hold → Sell
    Deutsche Bank
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    2/13/2025Neutral → Buy
    UBS
    2/12/2025Overweight
    Morgan Stanley
    11/20/2024Sell → Neutral
    UBS
    11/6/2024Sell → Hold
    Deutsche Bank
    More analyst ratings

    $AZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on AstraZeneca

    Citigroup initiated coverage of AstraZeneca with a rating of Buy

    1/27/26 8:43:14 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on AstraZeneca

    Jefferies resumed coverage of AstraZeneca with a rating of Buy

    10/27/25 8:41:53 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca downgraded by Deutsche Bank

    Deutsche Bank downgraded AstraZeneca from Hold to Sell

    10/16/25 8:19:10 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    SEC Filings

    View All

    $AZN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    4/9/26 1:01:44 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by AstraZeneca PLC

    25-NSE - ASTRAZENECA PLC (0000901832) (Subject)

    4/8/26 2:20:43 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    4/2/26 9:27:28 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Sharma Mani

    3 - ASTRAZENECA PLC (0000901832) (Issuer)

    3/19/26 7:51:36 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer

    IMFINZI plus IMJUDO combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial IMFINZI plus IMJUDO combined with lenvatinib and transarterial chemoembolization (TACE) showed trend toward improved overall survival Positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and transarterial chemoembolization (TACE) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of prog

    4/2/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

    First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduced the annualized rate of moderate-to-severe COPD exacerbations compared with placebo, in the primary population of former smokers, and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity. Tozorakimab was generally well tolerated with a fa

    3/27/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

    Joshua Jackson is joined by Gritty to take the body check off the ice. AstraZeneca and Joshua Jackson have teamed up as part of a national public health campaign designed to encourage fans to Get Body Checked Against Cancer and be proactive in speaking with their doctor. Joshua Jackson brings a unique cultural relevance to the initiative, resonating with a generation that grew up watching him on screen and is now entering a life stage where conversations about cancer risk and screenings become increasingly important. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310693422/en/Joshua Jackson teams up with Gritty and AstraZen

    3/10/26 8:30:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Leadership Updates

    Live Leadership Updates

    View All

    Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Walmart Inc. (NASDAQ:WMT), will become a component of the Nasdaq-100 Index® (NDX®), the Nasdaq-100 Equal Weighted™ Index (NDXE™), and the Nasdaq-100 Ex-Tech Sector™ Index (NDXX™) prior to market open on Tuesday, January 20, 2026 - the first trading day following the third Friday of the month. Walmart Inc. will replace AstraZeneca PLC (NASDAQ:AZN) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. AstraZeneca PLC will also be removed from the Nasdaq-100 ESG™ Index (NDXESG™), Nasdaq-100 ex Top 30™​ (NDX70™), Nasdaq-100 ex Top 30​ UCITS™ (NDX70U™), Nasdaq

    1/9/26 8:00:00 PM ET
    $AZN
    $NDAQ
    $WMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

    ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

    6/6/24 7:00:00 AM ET
    $AZN
    $IMAB
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Financials

    Live finance-specific insights

    View All

    AstraZeneca results: FY and Q4 2025

    Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period AstraZeneca: Revenue and EPS summary   FY 2025 % Change Q4 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 55,573 9 9 14,538 9 7 - Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 58,640 10 10 15,497 10 8 Collaboration Revenue 99 (89) (89) 6 (99) (99) Total Revenue 58,739 9 8 15,503 4

    2/10/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

    Submission based on positive BaxHTN Phase III trial results which demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with resistant or uncontrolled hypertension If approved, baxdrostat could be the first aldosterone synthase inhibitor to receive regulatory authorization AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with hard-to-control (uncontrolled or treatment resistant) hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pres

    12/2/25 9:18:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

    Baxdrostat demonstrated a statistically significant placebo-adjusted reduction of 13.9 mmHg in night-time ambulatory systolic blood pressure at 12 weeks with a safety profile consistent with the BaxHTN trial Full results presented at the American Heart Association Scientific Sessions 2025 Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care.1 Efficacy was observed throughout the

    11/9/25 4:33:00 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AstraZeneca PLC (Amendment)

    SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

    2/4/22 9:06:48 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

    2/3/21 1:13:21 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care